• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    INmune Bio Inc. - Common stock (NQ:INMB)

    1.870 -0.070 (-3.61%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 310,014
    Open 1.950
    Bid (Size) 1.820 (100)
    Ask (Size) 2.220 (200)
    Prev. Close 1.940
    Today's Range 1.820 - 1.978
    52wk Range 1.090 - 2.600
    Shares Outstanding 17,703,692
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    INmune Bio to Attend the 2026 Maxim Growth Summit
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
    From INmune Bio, Inc.
    Via GlobeNewswire

    Performance

    52-Week Range 28.1% below 52-week high
    1.870
    1.0952W Low 2.6052W High
    1 Week 7.4% below 1-week high
    1.881W Low 2.021W High

    INmune Bio Inc. - Common stock (INMB) traded between $1.09 and $2.60 over the past 52 weeks and last traded at $1.87, 28.1% below its 52-week high. Over the past week it ranged between $1.88 and $2.02.

    Past 12 Months
    -4.6%
    -25.5%
    +12.3%
    +52.0%
    +21.4%
    -9.2%
    1W -$0.09
    1M -$0.64
    3M +$0.21
    6M +$0.64
    YTD +$0.33
    1Y -$0.19

    INMB was -9.2% over the past year, +52.0% over six months, +21.4% year to date, -4.6% in the last week.

    12 Months vs Market
    INMB
    -9.2%
    DIA
    +10.2%
    SPY
    +16.0%
    QQQ
    +25.0%
    IWM
    +14.0%

    Over the past 12 months INMB returned -9.2% versus DIA (Dow) +10.2%, SPY (S&P 500) +16.0%, QQQ (Nasdaq 100) +25.0% and IWM (Russell 2000) +14.0%.

    Volume & Liquidity 0.69× 3-mo avg
    Today 310,014 3-mo avg 452.1K
    1W
    277.3K
    1M
    360.1K
    3M
    452.1K
    6M
    542.5K
    YTD
    506.1K
    1Y
    484.3K

    INMB most recently traded 310,014 shares against a 3-month average daily volume of 452.1K.

    More News

    Read More
    News headline image
    INmune Bio to Present at the H.C. Wainwright Global Investment Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio (INMB) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    INmune Bio (NASDAQ:INMB) Beats Q2 Loss Estimates but Shares Tumble on Business Update ↗
    Via Chartmill
    INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum ↗
    Via Chartmill
    News headline image
    INmune Bio Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    INmune Bio Receives R&D Rebates of Approximately $4.6 Million
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio (INMB) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio (INMB) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Topics Economy
    News headline image
    INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
    From INmune Bio, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is INmune Bio Inc. - Common stock publicly traded?
    Yes, INmune Bio Inc. - Common stock is publicly traded.
    What exchange does INmune Bio Inc. - Common stock trade on?
    INmune Bio Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for INmune Bio Inc. - Common stock?
    The ticker symbol for INmune Bio Inc. - Common stock is INMB on the Nasdaq Stock Market
    What is the current price of INmune Bio Inc. - Common stock?
    The current price of INmune Bio Inc. - Common stock is 1.870
    When was INmune Bio Inc. - Common stock last traded?
    The last trade of INmune Bio Inc. - Common stock was at 10/06/26 04:00 PM ET
    What is the market capitalization of INmune Bio Inc. - Common stock?
    The market capitalization of INmune Bio Inc. - Common stock is 33.11M
    How many shares of INmune Bio Inc. - Common stock are outstanding?
    INmune Bio Inc. - Common stock has 33M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.